Abstract

Background:There is an urgent need to look at New Models of Care to improve quality of care for patients whilst providing the best value for money. Community Pharmacy has been...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Assessment of four screening tools and retrieval of key questions to detect undiagnosed psoriatic arthritis in Chinese patients with psoriasis: A multicenter study.
Ran Cui ... Xia Li
The Journal of dermatology | VOL. 49
Ran Cui, et. al.Ran Cui ... Xia Li
22 Mar 2022
Psoriasis epidemiology screening tool (PEST) is useful for the detection of psoriatic arthritis in the Japanese population
Ayako Setoyama ... Yu Sawada
Scientific Reports | VOL. 11
Ayako Setoyama, et. al.Ayako Setoyama ... Yu Sawada
09 Aug 2021
Validation of the psoriasis epidemiology screening tool (PEST) and the new early arthritis for psoriatic patients (EARP) in pediatric population: pilot study.
Hadar Gavra ... Dan Ben-Amitai
Clinical rheumatology | VOL. 41
Hadar Gavra, et. al.Hadar Gavra ... Dan Ben-Amitai
14 Jan 2022
AB0744 Developing Thai Siriraj Psoriatic Arthritis Screening Tool and Validated Thai Psoriasis Epidemiology Screening Tool and The Early Arthritis for Psoriatic Patients
P Chiowchanwisawakit ... C Petcharat
Annals of the Rheumatic Diseases | VOL. 75
P Chiowchanwisawakit, et. al.P Chiowchanwisawakit ... C Petcharat
01 Jun 2016
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
Expert consensus recommendations for the diagnosis and treatment of chronic non-bacterial osteitis (CNO) in adults
Elizabeth M Winter ... Anne T Leerling
Annals of the Rheumatic Diseases | VOL. -
Elizabeth M Winter, et. al.Elizabeth M Winter ... Anne T Leerling
28 Nov 2024
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial
Jinjing Liu ... Xiaofeng Zeng
Annals of the Rheumatic Diseases | VOL. -
Jinjing Liu, et. al.Jinjing Liu ... Xiaofeng Zeng
27 Nov 2024
CD-19 CAR-T cells for polyrefractory rheumatoid arthritis
Merav Lidar ... Abraham Avigdor
Annals of the Rheumatic Diseases | VOL. -
Merav Lidar, et. al.Merav Lidar ... Abraham Avigdor
27 Nov 2024
Correction: Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment
-
Annals of the Rheumatic Diseases | VOL. -
--
27 Nov 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.